Kovitz Investment Group Partners LLC raised its position in shares of iShares Biotechnology ETF (NASDAQ:IBB – Get Rating) by 15.2% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 16,137 shares of the financial services provider’s stock after purchasing an additional 2,132 shares during the period. Kovitz Investment Group Partners LLC’s holdings in iShares Biotechnology ETF were worth $2,445,000 at the end of the most recent quarter.
Other hedge funds also recently added to or reduced their stakes in the company. Future Financial Wealth Managment LLC bought a new stake in shares of iShares Biotechnology ETF during the 4th quarter worth about $30,000. Gradient Investments LLC raised its position in shares of iShares Biotechnology ETF by 99.0% during the 4th quarter. Gradient Investments LLC now owns 201 shares of the financial services provider’s stock worth $31,000 after buying an additional 100 shares in the last quarter. Herold Advisors Inc. bought a new stake in shares of iShares Biotechnology ETF in the 3rd quarter worth approximately $32,000. Consolidated Planning Corp bought a new stake in shares of iShares Biotechnology ETF in the 3rd quarter worth approximately $32,000. Finally, Steward Financial Group LLC bought a new stake in shares of iShares Biotechnology ETF in the 4th quarter worth approximately $34,000. Institutional investors own 65.38% of the company’s stock.
Shares of NASDAQ IBB traded up $1.28 during midday trading on Tuesday, reaching $128.38. The company’s stock had a trading volume of 57,925 shares, compared to its average volume of 2,757,028. The company has a 50 day moving average price of $127.99 and a 200 day moving average price of $141.62. iShares Biotechnology ETF has a one year low of $118.60 and a one year high of $177.37.
About iShares Biotechnology ETF (Get Rating)
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Further Reading
- Get a free copy of the StockNews.com research report on iShares Biotechnology ETF (IBB)
- Workhorse Johnson & Johnson Plows New All-Time Highs
- Fastenal Stock is Ready to Sprint Higher
- J.B. Hunt Transportation Services Fires On All Cylinders
- 3 No-Brainer Stocks to Buy with $1000
- Rite Aid Stock is Getting Cheap Enough to Buy Here
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.